American Society of Hematology

banner image

Blood Advances

Explore the premiere issue of Blood Advances, ASH's new digital, open-access journal featuring innovative communication tools and expanded coverage of topics in Blood.

Learn more
banner image

ASH Sickle Cell Disease Initiative

Help ASH address the state of SCD treatment worldwide.

Learn more
banner image

2017 ASH Meeting on Hematologic Malignancies

Hear the top experts in hematologic malignancies discuss the latest developments in clinical care.

Learn more
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
  • Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit

    Trial results being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone. The study is the largest randomized controlled trial of post-transplant therapy for multiple myeloma ever conducted in the United States.

  • Cancer Drug Ibrutinib Found Helpful in Treating Graft Versus Host Disease After Stem Cell Transplant

    A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego shows patients who experience graft-versus-host disease (GVHD) after stem cell transplantation that is not resolved by corticosteroid treatment may benefit from the use of ibrutinib, an anti-cancer drug approved by the U.S. Food and Drug Administration for treating certain blood cancers.

  • First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma

    A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings. The study, which involved 22 institutions and tested a product called KTE-C19 (anti-CD19 CAR), is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma.

  • IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children

    A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego identifies inherited genetic mutations in the gene IKZF1 that confer a higher likelihood of developing pediatric acute lymphocytic leukemia (ALL). The findings are among the latest evidence to point to a strong inherited genetic basis of ALL risk in children. Some of the variants identified also appear to reduce cancer cells’ sensitivity to a chemotherapy drug used to treat some types of ALL, potentially contributing to drug resistance.

View all press releases
View all policy news
  • 2016 Medical Educators Institute

    Learn about what took place during the very first ASH Medical Educators Institute held at ASH Headquarters in Washington, DC during September of 2016.

  • A Stimulating Case of Leukocytosis

    Take the very first The Hematologist Image Challenge and try to figure out the diagnosis for a case of leukocytosis by looking at a peripheral blood smear.

  • ASH Standing Committee Update

    Drs. Sherif Badawy, Michael Linenberger, and Joseph Mikhael provide an overview of three ASH standing committees including each group's goals, mission, and new developments emerging from them.

  • The Saga of Theranos: Crucial Lessons for Clinicians and Pathologists

    Dr. George and Dr. Gullapalli provide a thorough synopsis of the history of Theranos, a medical and technological innovations laboratory company founded by Elizabeth Holmes.

View all Hematologist articles